ABBOTT LABORATORIES

ABT · CIK 0000001800

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$44.33B5.7%

FY2025

Net income (FY)

$6.52B51.3%

FY2025

Free cash flow (FY)

$7.39B16.4%

FY2025

Diluted EPS (FY)

$3.7251.3%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 1.7× since FY2007 · net margin 22.1% → 14.7%

MarginsNet marginFCF margin

FY2025: net 14.7% · free cash flow 16.7% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $9.57B operating cash − $2.17B capex = $7.39B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 19% (FY2011) → 13% (FY2025) · on assets 7.5%

The receipts

Financial statements

Annual Quarterly (as reported)

USD in millions except per-share and share counts. Every value links to the filing it came from — hover for the us-gaap tag, click for the 10-K/10-Q on sec.gov.

USD millions	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022
Revenue	11,164	11,369	11,142	10,358	10,635	10,377	9,964	10,143	9,978	9,747	10,410	11,257
Net income	1,077	1,644	1,779	1,325	1,646	1,302	1,225	1,436	1,375	1,318	1,435	2,018
Diluted EPS	0.61	0.94	1.01	0.76	0.94	0.74	0.70	0.82	0.78	0.75	0.81	1.14
Diluted shares	1,747	1,749	1,751	1,747	1,748	1,751	1,750	1,748	1,750	1,752	1,764	1,765
Operating cash flow	1,315	—	—	1,417	—	—	1,025	—	—	1,143	—	—
Capital expenditures	399	—	—	484	—	—	398	—	—	380	—	—
Free cash flow	916	—	—	933	—	—	627	—	—	763	—	—
Cash & equivalents	6,803	7,511	6,951	6,532	7,558	6,987	6,284	6,709	7,835	9,161	9,594	8,937
Total assets	110,429	84,181	83,999	81,448	74,356	73,017	72,467	72,090	73,354	73,794	72,801	74,202
Shareholders' equity	52,061	50,954	50,565	48,811	39,796	39,318	38,810	37,481	37,174	37,010	35,675	36,490

Figures as reported in SEC filings, normalized by stonks with the tag mapping shown on hover; missing tags render as “—”, never as zero. Free cash flow is derived (operating cash flow − capex) with both parents recorded in its lineage. Quarterly view shows as-reported 10-Q periods; Q4 synthesis ships in Phase 1. See methodology.